Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Paladin Labs Articles

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal

30 November 2011

Battle for Afexa escalates as suitors Valeant and Paladin up offers; Dr Reddy’s and JBCPL scrap Russian deal

27 September 2011

Valeant out-bids Paladin with C$76 million cash bid for Afexa

31 August 2011

Paladin Labs to buy troubled Labopharm in $20.6 million deal

22 August 2011

Paladin buys ex-US rights to Somaxon’s insomnia drug Silenor for up to $129 million

13 June 2011

Paladin gets $1 million in amended deal with Isotechnika; acquires Tempra from for Canada

4 February 2011

ProStrakan agrees refinancing and distribution deal with Paladin Labs

20 December 2010

Canadian drugmakers Labopharm and Paladin expand commercial relationship

15 October 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS